Jose M. Munoz-Felix

Dr. Jose M. Munoz-Felix

Department of Biochemistry and Molecular Biology, University of Salamanca, 37007 Salamanca, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Cell
Verified
Journal Article
Closed access
PWPing-Pui Wong
Ping-Pui Wong
JMJose M. Munoz-Felix
Jose M. Munoz-Felix
MARUAN HIJAZI VEGAMARUAN HIJAZI VEGA
MARUAN HIJAZI VEGA
HKHyojin Kim
Hyojin Kim
SRStephen D. Robinson
Stephen D. Robinson
KHKairbaan Hodivala-Dilke
Kairbaan Hodivala-Dilke

Verified
Journal Article
Open access
PDF file
IAIván Carrera Aguado
Iván Carrera Aguado
LMLaura Marcos-Zazo
Laura Marcos-Zazo
PCPatricia Carrancio-Salán
Patricia Carrancio-Salán
EPElena Guerra Paes
Elena Guerra Paes
FSFernando Sanchez
Fernando Sanchez
JMJose M. Munoz-Felix
Jose M. Munoz-Felix
Vessel co-option (VCO) is a non-angiogenic mechanism of vascularization that has been associated to anti-angiogenic therapy. In VCO, cancer cells hijack the pre-existing blood vessels and use them to obtain oxygen and nutrients and invade adjacent tissue. Multiple primary tumors and metastases undergo VCO in highly vascularized tissues such as the lungs, liver or brain. VCO has been associated with a worse prognosis. The cellular and molecular mechanisms that undergo VCO are poorly understood. Recent studies have demonstrated that co-opted vessels show a quiescent phenotype in contrast to angiogenic tumor blood vessels. On the other hand, it is believed that during VCO, cancer cells are adhered to basement membrane from pre-existing blood vessels by using integrins, show enhanced motility and a mesenchymal phenotype. Other components of the tumor microenvironment (TME) such as extracellular matrix, immune cells or extracellular vesicles play important roles in vessel co-option maintenance. There are no strategies to inhibit VCO, and thus, to eliminate resistance to anti-angiogenic therapy. This review summarizes all the molecular mechanisms involved in vessel co-option analyzing the possible therapeutic strategies to inhibit this process.

17 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ENEmma L. Newport
Emma L. Newport
APAna Rita Pedrosa
Ana Rita Pedrosa
ANAlexandra Njegic
Alexandra Njegic
KHKairbaan Hodivala-Dilke
Kairbaan Hodivala-Dilke
JMJose M. Munoz-Felix
Jose M. Munoz-Felix
Several strategies have been developed to modulate the tumour vasculature for cancer therapy including anti-angiogenesis and vascular normalisation. Vasculature modulation results in changes to the tumour microenvironment including oxygenation and immune cell infiltration, therefore lending itself to combination with cancer therapy. The development of immunotherapies has led to significant improvements in cancer treatment. Particularly promising are immune checkpoint blockade and CAR T cell therapies, which use antibodies against negative regulators of T cell activation and T cells reprogrammed to better target tumour antigens, respectively. However, while immunotherapy is successful in some patients, including those with advanced or metastatic cancers, only a subset of patients respond. Therefore, better predictors of patient response and methods to overcome resistance warrant investigation. Poor, or periphery-limited, T cell infiltration in the tumour is associated with poor responses to immunotherapy. Given that (1) lymphocyte recruitment requires leucocyte–endothelial cell adhesion and (2) the vasculature controls tumour oxygenation and plays a pivotal role in T cell infiltration and activation, vessel targeting strategies including anti-angiogenesis and vascular normalisation in combination with immunotherapy are providing possible new strategies to enhance therapy. Here, we review the progress of vessel modulation in enhancing immunotherapy efficacy.

24 May 2021 in Genes
Verified
Journal Article
Open access
PDF file
JMJose M. Munoz-Felix
Jose M. Munoz-Felix
CMCarlos Martinez-Salgado
Carlos Martinez-Salgado
Many different regulatory mechanisms of renal fibrosis are known to date, and those related to transforming growth factor-β1 (TGF-β1)-induced signaling have been studied in greater depth. However, in recent years, other signaling pathways have been identified, which contribute to the regulation of these pathological processes. Several studies by our team and others have revealed the involvement of small Ras GTPases in the regulation of the cellular processes that occur in renal fibrosis, such as the activation and proliferation of myofibroblasts or the accumulation of extracellular matrix (ECM) proteins. Intracellular signaling mediated by TGF-β1 and Ras GTPases are closely related, and this interaction also occurs during the development of renal fibrosis. In this review, we update the available in vitro and in vivo knowledge on the role of Ras and its main effectors, such as Erk and Akt, in the cellular mechanisms that occur during the regulation of kidney fibrosis (ECM synthesis, accumulation and activation of myofibroblasts, apoptosis and survival of tubular epithelial cells), as well as the therapeutic strategies for targeting the Ras pathway to intervene on the development of renal fibrosis.

28 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
BÍBlanca Ayuso Íñigo
Blanca Ayuso Íñigo
LGLucía Méndez García
Lucía Méndez García
MPMiguel Pericacho
Miguel Pericacho
JMJose M. Munoz-Felix
Jose M. Munoz-Felix
The improvement of cancer therapy efficacy, the extension of patient survival and the reduction of adverse side effects are major challenges in cancer research. Targeting blood vessels has been considered a promising strategy in cancer therapy. Since the tumor vasculature is disorganized, leaky and triggers immunosuppression and tumor hypoxia, several strategies have been studied to modify tumor vasculature for cancer therapy improvement. Anti-angiogenesis was first described as a mechanism to prevent the formation of new blood vessels and prevent the oxygen supply to tumor cells, showing numerous limitations. Vascular normalization using low doses of anti-angiogenic drugs was purposed to overcome the limitations of anti-angiogenic therapies. Other strategies such as vascular promotion or the induction of high endothelial venules are being studied now to improve cancer therapy. Bone morphogenetic protein 9 (BMP9) exerts a dual effect through the activin receptor-like kinase 1 (ALK1) receptor in blood vessel maturation or activation phase of angiogenesis. Thus, it is an interesting pathway to target in combination with chemotherapies or immunotherapies. This review manuscript explores the effect of the BMP9–ALK1 pathway in tumor angiogenesis and the possible usefulness of targeting this pathway in anti-angiogenesis, vascular normalization or vascular promotion therapies.

Verified
Journal Article
Open access
PDF file
DCDaniel Cáceres
Daniel Cáceres
ITIrene Torre-Cea
Irene Torre-Cea
LMLaura Marcos-Zazo
Laura Marcos-Zazo
IAIván Carrera Aguado
Iván Carrera Aguado
EPElena Guerra Paes
Elena Guerra Paes
FSFernando Sanchez
Fernando Sanchez
Metastasis is currently becoming a major clinical concern, due to its potential to cause therapeutic resistance. Its development involves a series of phases that describe the metastatic cascade: preparation of the pre-metastatic niche, epithelial–mesenchymal transition, dissemination, latency and colonization of the new tissue. In the last few years, new therapeutic targets, such as integrins, are arising to face this disease. Integrins are transmembrane proteins found in every cell that have a key role in the metastatic cascade. They intervene in adhesion and intracellular signaling dependent on the extracellular matrix and cytokines found in the microenvironment. In this case, integrins can initiate the epithelial–mesenchymal transition, guide the formation of the pre-metastatic niche and increase tumor migration and survival. Integrins also take part in the tumor vascularization process necessary to sustain metastasis. This fact emphasizes the importance of inhibitory therapies capable of interfering with the function of integrins in metastasis.